This study provides several essential indications regarding the impact of DDIs on the outcome of BRAFv600 MM patients treated with combined BRAF‐i/MEK‐i, offering insight into drug–drug interactions in a real‐world population. The gene discussed is BRAF; the disease is Miyoshi myopathy.